February 28, 2026 a 08:38 pm
REGN: Analysts Ratings - Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. stands strong in the biotech industry, driven by innovative treatments such as EYLEA and Dupixent. Analysts' sentiment reveals a cautious optimism reflected in the Buy ratings. Monitoring its product advancements and strategic collaborations will be key to assessing its market potential.
Historical Stock Grades
As of February 2026, the analyst ratings for Regeneron display a positive sentiment at 2 Strong Buys and 17 Buys, indicating robust support among analysts. No Sell recommendations align with a generally favorable outlook. The widespread Buy ratings underscore confidence in Regeneron's growth potential and product portfolio.
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 17 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment around Regeneron has experienced a slight shift towards caution, with some Strong Buy recommendations turning into Buys over the past months. Notably, the decrease in Strong Buys indicates a moderation of overly optimistic projections.
- The total number of recommendations has maintained stability with a minor shift in category weight.
- Strong Buy recommendations have decreased from 7 in early 2025 to 2 in early 2026.
- Buy recommendations have consistently formed the bulk of the sentiment, remaining high.
Percentage Trends
Recent months have illustrated a noticeable shift from Strong Buys to Buy recommendations, indicative of moderated optimism. The distribution of ratings suggests a cautious yet positive market outlook.
- Current ratings distribution emphasizes a majority Buy sentiment at 68%.
- A definitive reduction in Strong Buy percentages from around 25% to roughly 8% signals more cautious projections.
- Stable Hold recommendations indicate analysts' preference for holding positions amid market uncertainties.
Latest Analyst Recommendations
Recent analyst reports affirm existing sentiments, with Buy and Overweight ratings being maintained by influential institutions, reflecting continued confidence in Regeneron's prospects.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-09 | Buy | Buy | Guggenheim |
| 2026-02-02 | Buy | Buy | Truist Securities |
| 2026-02-02 | Overweight | Overweight | JP Morgan |
| 2026-02-02 | Equal Weight | Equal Weight | Morgan Stanley |
| 2026-02-02 | Equal Weight | Equal Weight | Wells Fargo |
Analyst Recommendations with Change of Opinion
Recent upgrades and downgrades by prominent firms reflect the evolving market dynamics for Regeneron, encapsulating both caution and opportunity recognition within their analysis.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-07 | Buy | Underperform | B of A Securities |
| 2025-12-03 | Equal Weight | Overweight | Morgan Stanley |
| 2025-05-30 | Equal Weight | Overweight | Wells Fargo |
| 2025-05-14 | Buy | Neutral | Citigroup |
| 2025-02-05 | Outperform | Market Perform | Leerink Partners |
Interpretation
From the analysis, it is evident that the market outlook for Regeneron shows growing optimism with caution. While recent downgrades epitomize cautious realism, the prevailing Buy sentiment affirms belief in Regeneron's potential. Despite a decrease in Strong Buys, the absence of Sell recommendations illustrates a trusted stability within its market position.
Conclusion
Regeneron Pharmaceuticals exhibits a solid standing within its industry, buoyed by strategic collaborations and a robust product lineup. While recent sentiment trends indicate a pivot towards cautious optimism, stable Buy ratings reflect an undercurrent of confidence. This balance of enthusiasm and caution illustrates potential growth, counterbalanced by inherent market and competitive risks. The anticipation of sustained product innovation will be pivotal for further bolstering market confidence and driving future sentiment.